Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema

BACKGROUND/AIMS: The RELIGHT clinical trial used an individualised treatment regimen of ranibizumab to treat diabetic macular oedema (DMO). We report findings from two patient-reported outcome instruments. METHODS: The National Eye Institute Visual Function Questionnaire (NEI-VFQ) was administered b...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakravarthy, Usha, Pearce, Ian, Banerjee, Sanjiv, Burton, Benjamin J L, Downey, Louise, Gale, Richard, Patel, Jignesh, Patra, Sudeshna, Sivaprasad, Sobha, Stevenson, Michael, Lupton, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528749/
https://www.ncbi.nlm.nih.gov/pubmed/31179389
http://dx.doi.org/10.1136/bmjophth-2018-000226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528749/
https://www.ncbi.nlm.nih.gov/pubmed/31179389
http://dx.doi.org/10.1136/bmjophth-2018-000226

Ejemplares similares